dslogo
azlogo

DESTINY-Breast06: Summary11. Curigliano G, Hu X, Dent R, et al. Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: primary results from DESTINY-Breast06. Presented at 2024 ASCO Annual Meeting; May 31-June 4, 2024; Chicago, Illinois. Presentation LBA1000.

  • T-DXd demonstrated a statistically significant and clinically meaningful PFS benefit vs TPC (chemotherapy) in HR+, HER2-low mBC in an earlier line of treatment than DESTINY-Breast04 
  • Results in HER2-ultralow were consistent with HER2-low
  • Confirmed ORR was 57.3% (T-DXd) vs 31.2% (TPC) in ITT
  • No new safety signals were identified; interstitial lung disease remains an important safety risk of T-DXd
  • DESTINY-Breast06 establishes T-DXd as an effective new treatment option for patients with HR+, HER2-low and HER2-ultralow mBC following ≥1 endocrine-based therapy

Abbreviations

HER2 = human epidermal growth factor receptor 2

;

HR = hormone receptor

;

ITT = intention-to-treat

;

mBC = metastatic breast cancer

;

mo = months

;

ORR = objective response rate

;

PFS = progression-free survival

;

T-DXd = Trastuzumab deruxtecan

;

TPC = Treatment of physician’s choice

References

1. Curigliano G, Hu X, Dent R, et al. Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: primary results from DESTINY-Breast06. Presented at 2024 ASCO Annual Meeting; May 31-June 4, 2024; Chicago, Illinois. Presentation LBA1000.

Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy. 

To help us improve our content for health care professionals, please take this short survey.

Feedback Survey

Document ID: c791d159-0a5c-4180-b38f-cd5e26050804
Last updated: 28-June-2024

©2023 AstraZeneca. All rights reserved.